Lenalidomida Fresenius Kabi (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This action modifies cytokine production, inhibits new blood‑vessel formation, and directly induces apoptosis and cell‑cycle arrest in malignant plasma cells.

The exact dose and schedule of Lenalidomida Fresenius Kabi are determined by the prescribing physician based on the patient’s specific disease state, prior treatments, renal function, and overall health. No fixed dosing information is provided here; clinicians must follow approved prescribing guidelines.

Lenalidomide is classified as a teratogenic agent and is contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for a defined period after discontinuation. Safety during breastfeeding has not been established, and nursing is generally discouraged while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to lenalidomide within the immunomodulatory drug class is thalidomide, while pomalidomide is a newer option. Lenalidomide generally offers a more favorable safety profile than thalidomide, with lower rates of peripheral neuropathy, but may require closer monitoring for cytopenias. Pomalidomide is often reserved for patients who have progressed after lenalidomide therapy.

Store Lenalidomida Fresenius Kabi at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Lenalidomida Fresenius Kabi is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include venous thromboembolism, severe neutropenia, secondary primary malignancies, and hepatic toxicity. Patients should be monitored for signs of blood clots, infections, unexplained bruising, and liver‑function abnormalities, and any concerning symptoms should be reported to a healthcare professional promptly.

Lenalidomida should not be used by patients with known hypersensitivity to lenalidomide or its excipients, pregnant or nursing women, and individuals with uncontrolled infections or severe hepatic impairment unless benefits outweigh risks. Clinicians must also evaluate contraindications related to concurrent use of certain anticoagulants or live vaccines.